Piper Sandler analyst David Amsellem raised the firm’s price target on Amneal Pharmaceuticals to $5 from $3 and keeps an Overweight rating on the shares post the Q2 report. With a strong lineup of recent and upcoming launches of non-oral solid generic products, visibility into the company’s EBITDA sustainability continues to improve, the analyst tells investors in a research note. The firm says the size of Amneal’s pipeline is large relative to the size of its current commercial portfolio.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMRX:
- Amneal Pharmaceuticals price target raised to $5 from $4 at Barclays
- Amneal Pharmaceuticals raises FY23 operating cash flow view to $220M-$250M
- Amneal Pharmaceuticals raises FY23 adjusted EPS view to 45c-55c from 40c-50c
- Amneal Pharmaceuticals reports Q2 adjusted EPS 19c, consensus 11c
- AMRX Upcoming Earnings Report: What to Expect?